Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex Pharmaceuticals Inc.’s new non-opioid ... The medication, called Journavx, was approved in the United States in January. The financial success of new drugs largely depends on how they ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...